ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
IPO Year: 1998
Exchange: NASDAQ
Website: iconplc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $340.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Neutral | Redburn Atlantic | |
| 9/18/2024 | $379.00 | Outperform | Leerink Partners |
| 6/6/2024 | $370.00 | Buy | Goldman |
| 12/15/2023 | $357.00 | Buy | Truist |
| 9/13/2023 | $306.00 | Outperform | TD Cowen |
| 1/17/2023 | $215.00 → $260.00 | Equal Weight → Overweight | Barclays |
| 1/13/2023 | Equal Weight → Overweight | Barclays | |
| 11/9/2022 | $265.00 → $260.00 | Neutral → Buy | BofA Securities |
| 9/7/2022 | $270.00 | Buy | UBS |
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public heal
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading healthcare intelligen
Collaboration with industry partners critical to support effective translation of new therapeutic approaches to the clinic ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics. Respondents acknowledged that much focus has been accorded to emerging oncology treatments; however, as of yet, there are varied views on the degree to which these precision approaches will improve patient outcomes. Significant inves
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 3:45 pm ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new inno
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 2024 and 9.9% on quarter two 2023. Quarter two revenue of $2,120.2 million representing an increase of 4.9% on prior year revenue and 5.3% on a constant currency basis. Quarter two adjusted EBITDA of $450.4 million or 21.2% of revenue, an increase of 8.7% on quarter two 2023. GAAP net income for the quarter of $146.9 million or $1.76 per diluted share, an increase of 25.7% on quarter two 2023 dilut
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director. Results of AGM All resolutions, which had all been recommended by the Board, were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 10, 2024 and are available on the ICON plc website. Fo
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 25, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading he
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations
6-K - ICON PLC (0001060955) (Filer)
S-8 - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G - ICON PLC (0001060955) (Subject)
Icon (NASDAQ:ICLR) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $3.68 by 1.9 percent. The company reported quarterly sales of $2.12 billion which missed the analyst consensus estimate of $2.14 billion by 0.95 percent. This is a 4.95 percent increase over sales of $2.02 billion the same period last year.
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 7.5% on an annualized basis producing an average annual return of 19.57%. Currently, Icon has a market capitalization of $27.50 billion. Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,480.44 today based on a price of $332.23 for ICLR at the time of writing. Icon's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
IQVIA Holdings Inc (NASDAQ:IQV) reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion. Sales increased 2.3% on a reported basis and 3.5% at constant currency compared to the second quarter of 2023. Technology & Analytics Solutions (TAS) revenue of $1.5 billion increased 2.7% on a reported basis and 3.8% at constant currency. Research & Development Solutions (R&DS) revenue reached $2.15 billion, increasing 2.4% on a reported basis and 3.3% at constant currency. Excluding the impact of pass-throughs, R&DS revenue grew 3.5% on a reported basis.
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.54% on an annualized basis producing an average annual return of 19.38%. Currently, Icon has a market capitalization of $26.56 billion. Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,462.72 today based on a price of $320.92 for ICLR at the time of writing. Icon's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by a
Baird analyst Eric Coldwell maintains Icon (NASDAQ:ICLR) with a Outperform and raises the price target from $367 to $376.
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%. Currently, Icon has a market capitalization of $26.32 billion. Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,425.55 today based on a price of $317.92 for ICLR at the time of writing. Icon's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by a
Goldman Sachs analyst Matthew Sykes initiates coverage on Icon (NASDAQ:ICLR) with a Buy rating and announces Price Target of $370.
TD Cowen analyst Charles Rhyee maintains Icon (NASDAQ:ICLR) with a Buy and raises the price target from $349 to $373.
Baird analyst Eric Coldwell maintains Icon (NASDAQ:ICLR) with a Outperform and raises the price target from $363 to $367.
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading healthcare intelligen
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 2024 and 9.9% on quarter two 2023. Quarter two revenue of $2,120.2 million representing an increase of 4.9% on prior year revenue and 5.3% on a constant currency basis. Quarter two adjusted EBITDA of $450.4 million or 21.2% of revenue, an increase of 8.7% on quarter two 2023. GAAP net income for the quarter of $146.9 million or $1.76 per diluted share, an increase of 25.7% on quarter two 2023 dilut
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 25, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading he
Highlights Net business wins in the quarter of $2,654 million; a net book to bill of 1.27, an increase of 9.9% on quarter one 2023. Closing backlog of $23.4 billion, an increase of 2.5% on quarter four 2023 and 10.1% on quarter one 2023. Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis. Quarter one adjusted EBITDA of $444.0 million or 21.2% of revenue, an increase of 11.3% on quarter one 2023. GAAP net income for the quarter of $187.4 million or $2.25 per diluted share, an increase of 59.6% on quarter one 2023 diluted earnings per share. Quarter one adjusted net income was $288.5 milli
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO. "On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his strong contributions to ICON over his 18 years, including 12 years as CFO," said Steve Cutler, ICON's CEO. "His effectiv
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 25, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading h
Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a year on year increase of 4.9%. Quarter four adjusted EBITDA of $448.2 million or 21.7% of revenue, an increase of 10.7% on quarter four 2022. Full year adjusted EBITDA of $1,694.1 million or 20.9% of revenue, representing a year on year increase
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 22, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc
Highlights Net business wins in the quarter of $2,581 million; a net book to bill of 1.26 or 1.22 on a trailing twelve month basis and an increase of 10% on quarter three 2022. Closing backlog of $22.2 billion, an increase of 2.6% on quarter two 2023 and an increase of 10.0% on quarter three 2022. Quarter three revenue of $2,055.1 million representing an increase of 5.8% on prior year revenue. YTD revenue of $6,053.9 million representing a year on year increase of 4.8%. Quarter three adjusted EBITDA of $432.5 million or 21.0% of revenue, an increase of 13.9% on quarter three 2022. YTD adjusted EBITDA of $1,245.9 million or 20.6% of revenue, representing a year on year increas
Robert W. Baird downgraded ICON plc from Outperform to Neutral and set a new price target of $340.00
Redburn Atlantic initiated coverage of ICON plc with a rating of Neutral
Leerink Partners initiated coverage of ICON plc with a rating of Outperform and set a new price target of $379.00
Goldman initiated coverage of ICON plc with a rating of Buy and set a new price target of $370.00
Truist initiated coverage of ICON plc with a rating of Buy and set a new price target of $357.00
TD Cowen initiated coverage of ICON plc with a rating of Outperform and set a new price target of $306.00
Barclays upgraded ICON plc from Equal Weight to Overweight and set a new price target of $260.00 from $215.00 previously
Barclays upgraded ICON plc from Equal Weight to Overweight
BofA Securities upgraded ICON plc from Neutral to Buy and set a new price target of $260.00 from $265.00 previously
UBS initiated coverage of ICON plc with a rating of Buy and set a new price target of $270.00